Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
You must be a Standard 1 Year member to access this content.
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its Series C financing, which totaled over $300 million. Tessera is a biotechnology company pioneering a...
You must be a Standard 1 Year member to access this content.
Goodwin advised LifeMine Therapeutics on the deal. LifeMine Therapeutics announced its completion of a $175 million Series C financing. LifeMine Therapeutics is reinventing drug discovery by mining...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Navitor Pharmaceuticals on the deal. Privately held Navitor Pharmaceuticals, LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies...
You must be a Standard 1 Year member to access this content.
